KCL22-s SMAD/TGFbeta Reporter (Luc) stable cell line

KCL22-s SMAD/TGFbeta Reporter (Luc) cells are derived from human lymphoblast-like cell line KCL22-s by stably integration of a SMAD/TGFbeta firefly luciferase reporter construct. KCL22-s cells are a variant of the KCL22 cell line that is sensitive to imatinib, a tyrosine kinase inhibitor commonly used to treat chronic myeloid leukemia (CML) . Imatinib targets the BCR-ABL fusion protein, which is a key driver of CML. The paired KCL22-s and KCL22-r clones are useful cell line models of sensitivity and resistance to imatinib. KCL22-s SMAD/TGFbeta Reporter (Luc) cells stably express firefly luciferase under the control of the SMAD/TGFbeta response elements, can be used for monitoring the activity of TGF?/SMAD signaling pathway.